Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trial
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2026.116817 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Ángel Guerrero-Zotano und 26 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Valenciano de Oncología (IVO), Valencia, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain. Electronic address: angel.guerrero.zotan…. Hauptthemen laut MEDLINE: Breast Neoplasms, Thymidine Kinase, Antineoplastic Combined Chemotherapy Protocols, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer Inc, AstraZeneca PLC.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto Valenciano de Oncología (IVO), Valencia, Spain; GEICAM Spanish Breast Cancer Group, Madrid, Spain. Electronic address: angel.guerrero.zotano@gmail.com.
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; Institut Català d'Oncologia (ICO) & IDIBELL, Servicio de Oncología Médica. L'Hospitalet. Barcelona, Spain.
- Biovica International AB, Sweden.
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; Medical Oncology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Servicio Oncología Médica, Madrid, Spain; Medical Oncology, HM Hospitales, Madrid, Spain; SOLTI Gr…
- GEICAM Spanish Breast Cancer Group, Madrid, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumours, August Pi I Sunyer Biomedical Resea…
Förderung
- Pfizer Inc
- AstraZeneca PLC
Zitieren
APA
Guerrero-Zotano, Á., Gil-Gil, M., Williams, A., Ruiz-Borrego, M., Ritzén, H., Ciruelos, E. M., Muñoz, M., Bermejo, B., Margelí, M., Antón, A., Kahan, Z., Csöszi, T., Murillo, L., Murillo, S. M., Lang, I., Rendo, C. R., Alba, E., Álvarez, P., de la Haba-Rodriguez, J., …, & Martín, M. (2026). Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116817
Vancouver
Guerrero-Zotano Á, Gil-Gil M, Williams A, Ruiz-Borrego M, Ritzén H, Ciruelos EM, et al. Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trial. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116817
BibTeX
@article{GuerreroZotano2026,
author = {Guerrero-Zotano, Ángel and Gil-Gil, Miguel and Williams, Amy and Ruiz-Borrego, Manuel and Ritzén, Hanna and Ciruelos, Eva María and Muñoz, Montserrat and Bermejo, Begoña and Margelí, Mireia and Antón, Antonio and Kahan, Zsuzsanna and Csöszi, Tibor and Murillo, Laura and Murillo, Serafín Morales and Lang, Istvan and Rendo, Cristina Reboredo and Alba, Emilio and Álvarez, Pablo and de la Haba-Rodriguez, Juan and Álvarez, Isabel and García, Andrés and Herranz, Jesús and Caballero, Rosalía and Fisker, Helle and Portela, Marta and Rojo, Federico and Martín, Miguel},
title = {Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trial},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2026.116817}
}
EUVIMED